Insiders Trades
Opko Health, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 20 Mar 2026.
Opko Health, Inc.: what insiders have been doing
Every trade that managers of Opko Health, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Miami, United States. It was founded in 1991. The last twelve months, up to 18 October 2026, brought 8 filings signed by 4 insiders.
Only purchases show up on the open market, 6 purchases in all worth €486k, filed by 2 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Frost Phillip Md Et al filed the largest purchase, €184k, on 31 October 2025. The buyers include 1 senior executive and 1 chief executive.
Compared with its exchange (5,816 companies, median 19 filings), a count of 8 filings is below the norm. Our records for Opko Health, Inc. go back to 2016, with 443 purchases and no sales on the open market in total. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 606.9 m USD and net income at -225.7 m USD.
The last purchase on record was published on 20 March 2026, which is 212 days ago.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
460
Thresholds
n/a
Buy Volume
€19M
443 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySalePhillip Md Et al Frost22 buys
John A. Paganelli1 buy
Since the insiders bought
- +24.3%Entry US$1.15 · Close at T+90 US$1.43
- -7.7%Entry US$1.30 · Close at T+90 US$1.20
- +48.5%Entry US$1.01 · Close at T+365 US$1.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Opko Health, Inc. Buy (bullish), based on 4 analysts. Average price target: US$4.63.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,493 of 24,148 companies
18.5
score / 100
Value12
Quality26
FCF yld-16%
Earn yld-19%
EV/EBITDA·
ROE-5.9%
Gross mgn34%
Net mgn-37%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.61
Analyst consensus
4 analystsBuy
US$3.00Target US$4.63(+187%)US$8.50
Income statement
RevenueUS$606.9M
Gross profitUS$205.9M34% margin
EBITDA-US$41.3M-7% margin
Net income-US$225.7M-12.4% margin
Valuation
PER (forward)-4.7x
P/Book1.0x
Beta1.50
Balance sheet & cash
Market capUS$1.2B
Total debtUS$396.8M
Free Cash Flow-US$190.8M
Debt / Equity34%
Profitability & ownership
ROE-5.9%
ROA-5.5%
% insiders50.5%
% institutions27.6%
Last declaration on 28 July 2026
Declarations460 total
53,266 shares@ US$1.220.0053% mcap100.0% of flowCommon StockSEC:0001193125-26-321055:0
53,266 shares@ US$1.220.0053% mcap73.9% of flowCommon StockSEC:0001193125-26-321041:0
10,000 shares@ US$1.13532.7% of flowCommon StockSEC:0001193125-26-117703:0
Canonical exit: 18 Jun 2026 (T+90)
102,371 shares@ US$1.300.6% of flowCommon StockSEC:0001193125-25-291590:0
Canonical exit: 19 Feb 2026 (T+90)
119,129 shares@ US$1.320.7% of flowCommon StockSEC:0001193125-25-290115:0
Canonical exit: 18 Feb 2026 (T+90)
36,325 shares@ US$1.280.2% of flowCommon StockSEC:0001193125-25-288284:0
Canonical exit: 17 Feb 2026 (T+90)
410 shares@ US$1.2450.0% of flowCommon StockSEC:0001193125-25-286448:0
Canonical exit: 16 Feb 2026 (T+90)
150,000 shares@ US$1.42291.0% of flowCommon StockSEC:0001193125-25-260956:0
Canonical exit: 29 Jan 2026 (T+90)
440,000 shares0Common StockSEC:0000950170-25-110094:0
675,000 shares@ US$1.324.1% of flowCommon StockSEC:0000950170-25-105971:0
Canonical exit: 6 Nov 2025 (T+90)
125,000 shares@ US$1.35770.8% of flowCommon StockSEC:0000950170-25-052925:0
Canonical exit: 9 Jul 2025 (T+90)
125,000 shares@ US$1.47720.9% of flowCommon StockSEC:0000950170-25-052214:0
Canonical exit: 7 Jul 2025 (T+90)
100,000 shares@ US$1.64850.8% of flowCommon StockSEC:0000950170-25-048737:0
Canonical exit: 30 Jun 2025 (T+90)
150,000 shares@ US$1.69591.3% of flowCommon StockSEC:0000950170-25-046952:0
Canonical exit: 26 Jun 2025 (T+90)
200,000 shares@ US$1.73911.7% of flowCommon StockSEC:0000950170-25-040497:0
Canonical exit: 15 Jun 2025 (T+90)
67,434 shares@ US$1.710.6% of flowCommon StockSEC:0000950170-25-030278:0
Canonical exit: 29 May 2025 (T+90)
47,537 shares@ US$1.47380.4% of flowCommon StockSEC:0000950170-25-009978:0
Canonical exit: 28 Apr 2025 (T+90)
150,000 shares@ US$1.46951.2% of flowCommon StockSEC:0000950170-25-006790:0
Canonical exit: 17 Apr 2025 (T+90)
500,000 shares@ US$1.48173.9% of flowCommon StockSEC:0000950170-25-005908:0
Canonical exit: 15 Apr 2025 (T+90)
125,000 shares@ US$1.5951.0% of flowCommon StockSEC:0000950170-24-136264:0
Canonical exit: 13 Mar 2025 (T+90)
500,000 shares@ US$1.56214.0% of flowCommon StockSEC:0000950170-24-135471:0
Canonical exit: 11 Mar 2025 (T+90)
199,072 shares@ US$1.5341.6% of flowCommon StockSEC:0000950170-24-131871:0
Canonical exit: 27 Feb 2025 (T+90)
100,000 shares@ US$1.590.8% of flowCommon StockSEC:0000950170-24-130292:0
Canonical exit: 20 Feb 2025 (T+90)
100,000 shares@ US$1.61980.8% of flowCommon StockSEC:0000950170-24-127266:0
Canonical exit: 12 Feb 2025 (T+90)
280,183 shares@ US$1.50452.1% of flowCommon StockSEC:0000950170-24-124261:0
Canonical exit: 6 Feb 2025 (T+90)
25 of 460 declarations
About Opko Health, Inc.
OPKO Health, Inc. (ticker: OPK) is a U.S.-listed healthcare company traded on the NASDAQ in the United States. Headquartered in Miami, Florida, at 4400 Biscayne Boulevard, OPKO presents itself as a fully integrated healthcare platform combining pharmaceuticals, diagnostics, and research-driven drug development. For French-, Belgian- and Swiss-based investors, it is best understood as a hybrid healthcare group: part commercial pharma company, part clinical diagnostics operator, and part biotech with pipeline optionality.
The company’s roots trace back to Dr. Phillip Frost, a well-known figure in U.S. biopharma, and OPKO adopted its current name in 2007. Since then, the group has built a diversified model around large healthcare markets rather than relying on a single asset. Its main business lines include Pharmaceuticals, Diagnostics, and Research. In pharmaceuticals, OPKO markets products such as RAYALDEE® and has exposure to NGENLA™ through a partnership model. In diagnostics, the company operates BioReference Laboratories, which OPKO describes as one of the largest full-service clinical reference laboratories in the United States, serving approximately 11 million patients annually. On the innovation side, OPKO is developing next-generation multispecific biologics through its wholly owned subsidiary ModeX Therapeutics.
Read moreShow less
From a competitive standpoint, OPKO operates in highly contested markets where scale, reimbursement, regulatory execution, and scientific differentiation matter. The company’s strategy is not simply to compete as a standalone commercial manufacturer, but to combine recurring operating businesses with partnered development programs and broader scientific collaborations. That approach gives OPKO multiple potential value drivers: diagnostic cash generation, product commercialization, and pipeline milestones. The company has highlighted partnerships with leading organizations including Pfizer, Merck, BARDA, the NIH, Regeneron, CSL Vifor, and Entera Bio, which supports its credibility as a collaborator in advanced healthcare research.
Geographically, OPKO has a meaningful international footprint, with operating businesses in the United States, Mexico, Chile, Spain, Ireland, and Israel, and broader commercialization reach through partnerships in additional markets. Recent developments have been particularly important for the investment case. In 2025 and 2026, OPKO reported progress for ModeX programs, including clinical advancement of multispecific antibody candidates and the initiation of a Phase 1 study for a tetraspecific antibody in B-cell lymphomas. The company also expanded its collaboration with Entera Bio to advance an oral long-acting PTH tablet for hypoparathyroidism. In parallel, OPKO continued to reshape its diagnostics portfolio, including the sale of select oncology-related testing assets to Labcorp. Overall, OPKO remains a diversified healthcare story with a mix of established revenues, partnership monetization, and clinical-stage upside on the NASDAQ in the United States.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
